This contract expires in 366 days (Jul 9, 2027).
THE INSTITUTE FOR CANCER RESEARCH - COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS
Key Details
Description
COLORECTAL CANCER (CRC) PREVENTION BY UROLITHIN A IN RODENT CRC MODELS
Context & Analysis
On Jan 29, 2026, Department of Health and Human Services obligated $1,038,958 to THE INSTITUTE FOR CANCER RESEARCH for colorectal cancer (crc) prevention by urolithin a in rodent crc models. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in PHILADELPHIA, PA. The contract is scheduled through Jul 9, 2027 — approximately 12 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.